3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
2
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Carcinoma, Non-Small-Cell Lung
92
Breast Neoplasms
85
Neoplasms
79
Prostatic Neoplasms
50
Lung Neoplasms
43
Neoplasm Metastasis
40
Colorectal Neoplasms
37
Leukemia, Myeloid, Acute
32
Pain
27
Head and Neck Neoplasms
25
Colonic Neoplasms
25
Multiple Myeloma
24
Ovarian Neoplasms
23
Lymphoma
23
Carcinoma, Hepatocellular
23
Pancreatic Neoplasms
22
Lymphoma, Follicular
21
Melanoma
20
Leukemia
20
Rectal Neoplasms
19
Lymphoma, Non-Hodgkin
19
Urinary Bladder Neoplasms
17
Recurrence
17
Stomach Neoplasms
15
Lymphoma, Large B-Cell, Diffuse
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Squamous Cell Carcinoma of Head and Neck
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Leiomyoma
13
Brain Neoplasms
13
Interventions
donafenib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Terminated
×
Differentiated Thyroid Cancer
×
Clear all
NCT03602495
2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Terminated
204 enrolled
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts